---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-300047"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2021-10-15T23:59:59+00:00"
generated_at: "2026-06-28T20:43:00.995084+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sarepta prices $500M common stock offering; preliminary Q3 revenue up 37% to $166.9M

## Summary
- Preliminary Q3 2021 net product revenue of ~$166.9M, up from $121.4M in Q3 2020.
- Cash, cash equivalents and investments were ~$1.6B as of Sept 30, 2021, down from $1.9B at Dec 31, 2020.
- Priced public offering of 6,172,840 shares at $81.00/share for gross proceeds of $500M; net proceeds ~$549.1M.
- Underwriters granted 30-day option for additional 925,926 shares, exercised in full; closing expected Oct 18, 2021.
- Proceeds to fund clinical trials, commercialization, manufacturing, and potential acquisitions.

## SEC filing metadata
- accession: 0001193125-21-300047
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2021-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000119312521300047/0001193125-21-300047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000119312521300047/d228298d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-300047
- JSON: https://secwatch.observer/filing/0001193125-21-300047.json
- Plain text: https://secwatch.observer/filing/0001193125-21-300047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.